IONS Ionis Pharmaceuticals Inc

Price (delayed)

$61.27

Market cap

$8.57B

P/E Ratio

120.14

Dividend/share

N/A

EPS

$0.51

Enterprise value

$8.75B

Sector: Healthcare
Industry: Biotechnology

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights

IONS's revenue is up by 14% YoY
The gross profit is up by 13% year-on-year
IONS's P/E is 112% above its last 4 quarters average of 56.8
Ionis Pharmaceuticals's EPS has shrunk by 84% YoY and by 45% QoQ

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
139.82M
Market cap
$8.57B
Enterprise value
$8.75B
Valuations
Price to earnings (P/E)
120.14
Price to book (P/B)
6.19
Price to sales (P/S)
9.18
EV/EBIT
57.03
EV/EBITDA
52.15
EV/Sales
9.39
Earnings
Revenue
$932.66M
EBIT
$153.5M
EBITDA
$167.88M
Free cash flow
$178.11M
Per share
EPS
$0.51
Free cash flow per share
$1.27
Book value per share
$9.9
Revenue per share
$6.68
TBVPS
$21.96
Balance sheet
Total assets
$3.1B
Total liabilities
$1.49B
Debt
$820.66M
Equity
$1.38B
Working capital
$2.29B
Liquidity
Debt to equity
0.59
Current ratio
10.37
Quick ratio
9.68
Net debt/EBITDA
1.12
Margins
EBITDA margin
18%
Gross margin
99%
Net margin
7.9%
Operating margin
11.9%
Efficiency
Return on assets
2.3%
Return on equity
5.3%
Return on invested capital
5%
Return on capital employed
5.4%
Return on sales
16.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
-2.03%
1 week
-0.13%
1 month
10.72%
1 year
2.08%
YTD
8.37%
QTD
8.37%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$932.66M
Gross profit
$923.01M
Operating income
$111.24M
Net income
$73.4M
Gross margin
99%
Net margin
7.9%
The company's net margin has shrunk by 85% YoY and by 43% QoQ
The net income has dropped by 83% year-on-year and by 44% since the previous quarter
IONS's operating income is down by 26% since the previous quarter and by 4.1% year-on-year
The operating margin has declined by 26% since the previous quarter and by 16% year-on-year

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
120.14
P/B
6.19
P/S
9.18
EV/EBIT
57.03
EV/EBITDA
52.15
EV/Sales
9.39
IONS's P/E is 112% above its last 4 quarters average of 56.8
Ionis Pharmaceuticals's EPS has shrunk by 84% YoY and by 45% QoQ
The stock's price to book (P/B) is 64% less than its 5-year quarterly average of 17.4 but 17% more than its last 4 quarters average of 5.3
The company's equity rose by 3.5% YoY
The P/S is 23% less than the 5-year quarterly average of 11.9 but 21% more than the last 4 quarters average of 7.6
IONS's revenue is up by 14% YoY

Efficiency

How efficient is Ionis Pharmaceuticals business performance
IONS's return on equity has dropped by 85% year-on-year and by 44% since the previous quarter
IONS's return on assets has dropped by 85% year-on-year and by 45% since the previous quarter
Ionis Pharmaceuticals's return on sales has decreased by 30% YoY and by 20% QoQ
Ionis Pharmaceuticals's ROIC has decreased by 25% YoY and by 21% from the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 108% greater than the total liabilities
The company's debt is 41% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.